Sarepta Therapeutics sales outlook dips after Q4 miss
The Sarepta Therapeutics sales outlook has been affected by challenges in commercializing its gene therapy, leading to decreased investor confidence and
Nvidia Eli Lilly AI investment: $1B in AI-focused lab to
Nvidia Eli Lilly AI investment exemplifies a strategic partnership aiming to accelerate drug discovery through advanced AI applications in pharmaceutical
Sanofi Dren Bio deal: $1.8B collaboration in immune medicine
The Sanofi Dren Bio deal involves Sanofi's acquisition of Dren Bio in a potential $1.8 billion investment to expand its immunology portfolio and develop
Novo Nordisk stock decline as weight-loss drug craze fades
The Novo Nordisk stock decline in 2023 has caused stock prices to retreat amid volatility and changing market conditions, prompting investors to reassess its
Medicare Novo Nordisk discounts: US government secures 71%
The U.S. government announced Medicare Novo Nordisk discounts on Ozempic and Wegovy, offering a 71% price reduction to improve access and affordability for
Bayer’s Experimental Stroke Prevention Drug Shows Promise
Bayer AG announced positive results from a late-stage clinical trial of an experimental stroke prevention drug, demonstrating its potential to reduce stroke
Bayer quarterly profit surpasses expectations on strong
Bayer quarterly profit exceeded analyst expectations, driven by strong sales in pharmaceuticals and agricultural seeds, reflecting positive momentum across its
Novartis acquisition Avidity: Nearing Deal to Acquire
Novartis acquisition Avidity reflects Novartis's strategic effort to expand its biotech portfolio and enhance its R&D capabilities in gene therapy and RNA
Novo Halves Ozempic Price to $499 Monthly for Cash Customers, Details on Bloomberg Intelligence
Novo Nordisk has announced a significant reduction in the out-of-pocket cost for Ozempic, its popular diabetes medication. The company has lowered the cash price to $499 a month, making the…
Boehringer Ingelheim Secures U.S. Approval for Groundbreaking Lung Cancer Drug,
Boehringer Ingelheim has received approval from U.S. regulatory authorities for its new drug aimed at treating a difficult form of lung cancer. This authorization marks a significant milestone for the…